Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization ...
Breaking Down Ultragenyx Pharmaceutical: 7 Analysts Share Their Views
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $98.0, a ...
Ultragenyx Pharmaceutical’s (RARE) Buy Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) in a report ...
manilatimes9d
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
Total operating expenses for the fourth quarter of 2024 were $287 million, including non-cash stock-based compensation of $40 ...
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
Last week, you might have seen that Ultragenyx Pharmaceutical Inc. ( NASDAQ:RARE ) released its yearly result to ...
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
RARE reports mixed fourth-quarter results, as earnings miss estimates while revenues beat the same. Product sales increase year over year.
Investing5d
Ultragenyx's SWOT analysis: rare disease biotech stock eyes pivotal year
Ultragenyx has demonstrated solid financial performance in recent quarters, beating revenue expectations and raising guidance. In its most recent quarter, the company reported revenue of $147 ...
Ultragenyx’s BLA for UX111 accepted by FDA for priority review
Ultragenyx (RARE) announced the FDA has accepted for review the Biologics License Application, or BLA, seeking accelerated approval for UX111 ...
ETF Daily News3d
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) had its price objective hoisted by Canaccord Genuity Group from $121.00 to $136.00 in a report released on Tuesday,Benzinga reports.
Ultragenyx price target raised to $136 from $121 at Canaccord
Canaccord analyst Whitney Ijem raised the firm’s price target on Ultragenyx (RARE) to $136 from $121 and keeps a Buy rating on the shares. The ...